

Indian pharmaceuticals industry is on path to improve its infrastructure and technical capabilities. The industry is now actively making efforts to work towards import substitution through a task force constituting various stakeholders that include government officials, Pharmaexcil, manufacturers, CSIR (Council of Scientific and Industrial Research) labs and others. The task force is identifying top 100 imported raw materials and products. These products could be individually or jointly developed. Several modalities are being worked out now and the outcomes will be seen in the next few months.

“The industry is expecting a healthy growth of 12-15 per cent CAGR in value terms and 10 per cent year-on-year growth in pharmaceutical exports this year. “We are seeing some improvement in the indigenisation and domestic manufacturing in the pharmaceutical equipment and machinery. There is still large dependency on imported equipment. Industry finds it still unviable to make certain machinery as the market is very competitive. Import substitution may improve in the years to come,” he added.

Special invitee Dr. Rao Vadlamuri, President, Indian Pharmaceutical Association (IPA), in his address, said: “It



Special invitee Mr. Avinash Talwar, Director & Head, Global Sourcing, Dr Reddy's Lab, speaks.

ACHEMA
2018 11 - 15 June
 Frankfurt / Main

BE INFORMED. BE INSPIRED. BE THERE.

- World Forum and Leading Show for the Process Industries
- 3,800 Exhibitors from 50 Countries
- 170,000 Attendees from 100 Countries

ProcessAutomation@ACHEMA
 THE KEY TO FLEXIBILITY AND COMPETITIVENESS
 #processautomat

www.achema.de

